Literature DB >> 25877729

Myasthenia gravis and neuromyelitis opica: A causal link.

J Spillane1, G Christofi2, K C Sidle3, D M Kullmann3, R S Howard2.   

Abstract

Neuromyelitis Optica (NMO) and Myasthenia Gravis (MG) are rare antibody mediated disorders of the central nervous system (CNS) and neuromuscular junction (NMJ) respectively. Both diseases are predominantly mediated by IgG1 antibodies that activate complement. There have been increasing reports of patients who develop both disorders. Given the rarity of both diseases it would seem that these occurrences are not purely coincidental. There is heterogeneity between the cases described in the literature but common trends are observed in patients who develop both disorders. Most patients described are female. Typically the MG precedes the NMO and the majority of patients have undergone thymectomy. Generally, the symptoms of MG are mild but the NMO tends to follow a more aggressive clinical course. The pathogenesis of NMO in combination with MG is unknown, but thymectomy has been implicated in a subset of patients. We present the case of a female patient who developed NMO on a background of sero-positive MG and discuss the relevant literature.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetylcholine receptor (AChR) antibody; Aquaporin-4 (AQP4) antibody; Longitudinally extensive transverse myelitis; Myasthenia Gravis; Neuromyelitis Optica; Thymectomy

Year:  2013        PMID: 25877729     DOI: 10.1016/j.msard.2013.01.003

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  2 in total

1.  NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.

Authors:  Tehila Mizrachi; Livnat Brill; Malcolm Rabie; Yoram Nevo; Yakov Fellig; Mayan Zur; Dimitrios Karussis; Oded Abramsky; Talma Brenner; Adi Vaknin-Dembinsky
Journal:  J Immunol Res       Date:  2018-05-22       Impact factor: 4.818

Review 2.  Myasthenia gravis: a clinical-immunological update.

Authors:  Sophie Binks; Angela Vincent; Jacqueline Palace
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.